ABTC-1403- Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide

The purpose of this study is to find the best dose of a study drug, NT-I7, given after radiation and chemotherapy. NT-I7 is an interleukin-7 (IL-7), a protein to increase CD4 counts. This study tests different doses of NT-I7 to see which dose is safer in people with brain cancer who have received standard radiation therapy with temozolomide. Adult subjects with a diagnosis of HGG and severe treatment-related CD4 Lymphopenia after concurrent radiation and temozolomide. Subjects for this study will be recruited from the patient population that present to the Department of Neurosurgery at the Hospital of the University of Pennsylvania for evaluation and treatment of their brain tumors.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Glioblastoma
• Age: Between 18 Years - 99 Years
• Gender: All